Clinical Trial Update: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) [Phase 1]

View source ↗

Summary

Phase 1 study MagnetisMM-30 is evaluating the combination of elranatamab and iberdomide in relapsed or refractory multiple myeloma; the trial is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)
• iberdomide (iberdomide)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING